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Pregnancya b s t r a c t
Preeclampsia is a multifactorial vascular disease unique to human pregnancy. While genetic and
antiangiogenic factors are important contributors to preeclampsia susceptibility, recent studies have
shown that dysregulation and/or over-activation of the complement system has an integral role in dis-
ease etiology. Furthermore, the role of the coagulation cascade may be underappreciated in the develop-
ment of the disease. Traditionally, for research purposes, the pool of preeclampsia cases has been divided
into non-severe and severe disease depending on the onset and severity of the symptoms. However, of
particular interest are a small but important minority of cases that present with symptoms likening to
those of hemolysis, elevated liver enzymes and low platelets syndrome, atypical hemolytic uremic syn-
drome, or thrombotic thrombocytopenic purpura, all thrombotic microangiopathy (TMA) diseases, with
the hallmark mechanisms of endothelial dysfunction and aberrant activation of complement and coagu-
lation cascades. We therefore propose a third class, severe TMA-like preeclampsia to be included in the
categorization of preeclampsia patients. Identifying these patients would target research, diagnostic dif-
ferentiation, and novel treatment options to the subclass of patients with life-threatening disease that are
most likely to benefit from next-generation drug development.
 2021 The Authors. Published by Elsevier Inc. on behalf of American Society for Histocompatibility and
Immunogenetics. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).1. Introduction
Preeclampsia is characterized by newly onset hypertension and
proteinuria during pregnancy, or in the absence of proteinuria, any
of following features of severe preeclampsia: thrombocytopenia,
renal insufficiency, impaired liver function, pulmonary edema,
new-onset headache [1]. During pregnancy, maternal immune sys-
tem is challenged especially locally in the decidua. Appropriate
immune regulation has to take place to tolerate placental cells
invading into the uterine tissue and maternal vascular walls.Development of the placenta is crucial in determining the fate of
the pregnancy.
Preeclampsia is a multifactorial disease and accordingly, the
clinical presentation of the disease is highly variable. Symptoms
vary from mild maternal hypertension and proteinuria without
obvious effects on the fetus to severe growth retardation of the
fetus combined with systemic maternal disease. In severe cases,
preeclampsia may lead to organ failure affecting vasculature, kid-
neys and liver and result in coagulopathy and eclampsia. HELLP
syndrome is characterized by hemolysis, elevated liver enzymes
and low platelets. It may occur independently, but is often consid-
ered preeclampsia-related. If HELLP syndrome is diagnosed during
pregnancy, the delivery of the infant is usually imminent irrespec-
tive of the length of the pregnancy, often leading to prematurity
and intensive care level treatment of the mother. HELLP syndrome,
like preeclampsia, may be diagnosed after the delivery. Some
preeclampsia patients show signs of hemolysis, elevated liver
enzymes and low platelets in the laboratory parameters without
fulfilling the strict diagnostic criteria of HELLP syndrome [2]. Previ-
ously, these patients were categorized as incomplete/partial HELLP
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with severe features [1].
In the first part of this review, we describe the role of the com-
plement system, endothelium, and angiogenesis in pregnancy and
recapitulate TMA disease mechanisms. In the second part, we revi-
sit these topics to highlight their interactions and role in
preeclampsia pathogenesis. Finally, a novel diagnostic category,
the TMA-like preeclampsia disease is proposed in the third part.
1.1. Complement system
The complement system comprises of more than forty soluble
and membrane-bound protein components that interact with each
other resulting in a tightly regulated stepwise network of activa-
tion and regulation. Complement system is an integral part of
the innate immune system responsible for inflammation, self/non-
self discrimination, and clearance of damaged cells and foreign
particles, including pathogens. Upon activation of the complement
system by classical pathway via immunocomplexes, CRP and C1q
binding, vasodilation occurs. Alternative pathway of the comple-
ment system may activate spontaneously by C3b deposition to a
target structure lacking the sialic acid and glycosaminoglycan
structures on host cells that allow for protection from complement
activation by binding of factor H, a potent soluble complement
inhibitor [3]. In the presence of factor H, complement C3 is cleaved
and the C3b component attaches covalently to the target surface
and is then inactivated by factor I to form iC3b. In the context of
pregnancy, the third pathway of complement activation, lectin
pathway, has received least attention. All pathways of complement
activation lead to cleavage of C3 and formation of C5-convertases
that have the capacity to activate the terminal pathway. Terminal
pathway activation culminates in creation of the membrane attack
complex (MAC), a pore structure that results in target cell lysis.
1.2. Clearance of placental debris is crucial for healthy pregnancy
Placenta is a transient rapidly growing organ responsible for
maintaining the developing fetus during pregnancy. During the
first trimester, the placental trophoblast cells invade into the
decidua and further into the spiral arteries and other structures
in the myometrium [4]. In the spiral arteries, the endothelialized
trophoblast cells program the re-modulation of the spiral artery,
thereby creating optimal high-flow, low-pressure conditions for
the maternal blood flow into the placental intervillous space. The
placenta sheds trophoblast debris into maternal circulation. The
trophoblast components range from nanovesicles to multinucle-
ated syncytial nuclear aggregates. In a healthy pregnancy, the tro-
phoblast components result from normal turnover of the
syncytium layer, which covers the placental villous trees and they
are shed in moderation. Trophoblast particles in the maternal cir-
culation are considered to induce peripheral tolerance.
1.3. Angiogenic balance during pregnancy
Increase of anti-angiogenic circulating factors soluble endoglin
and soluble receptor fms-like tyrosine kinase 1 (sFlt1, soluble vas-
cular endothelial growth factor receptor 1 sVEGFR1) are associated
with increased risk of preeclampsia [5]. sFlt1 is predominantly
expressed by trophoblast cells, endothelia, and inflammatory cells
[6], and it is a soluble antagonist of vascular endothelial growth
factor (VEGF) and placental growth factor (PIGF). In second and
third trimesters of a healthy pregnancy, PlGF is more abundant
than its ligand, sFlt1. When the levels of sFlt1 exceed levels of PlGF,
placental development is compromised [7]. In the pregnant
woman, sFlt1 limits vascular remodeling and neovasculogenesis372while restricting growth of the placenta [8]. Furthermore, sFlt1
may act in an anti-inflammatory capacity [9].
1.4. Endothelium
The feto-maternal boundary consists of endothelia. Integrity of
the endothelium is crucial to the successful pregnancy. The syncy-
tiotrophoblast is a specialized endothelium that circumferentially
encapsulates the placental villi. This proximal boundary is conven-
tionally seen as the feto-maternal boundary. As placental extracel-
lular material and apoptotic cells are peppered into the maternal
circulation, it could be argued, that endothelia within the maternal
vasculature and organs serve as a distal feto-maternal boundary
and are therefore the target of potential endothelial damage due
to the pregnancy. Dysfunction of the endothelium during preg-
nancy may thus result in maternal systemic symptoms and organ
failure.
1.5. Coagulation disturbance is at the heart of the TMA
Thrombotic microangiopathy (TMA) is a group of diseases char-
acterized by microangiophatic hemolysis, thrombocytopenia and
microthrombi formation leading to ischemic tissue injury [10].
TMA is caused by endothelial injury in the microcirculation
with activation of the complement system and/or coagulation cas-
cade. This leads to ongoing thrombosis caused by platelet aggrega-
tion and mechanical breakdown of erythrocytes passing through
the capillary vessels. Resulting thrombus formation causes ische-
mia and infarction in the end organ, and often affects the kidneys,
brain, gastrointestinal tract, and heart. Symptoms are usually non-
specific and in extreme cases, result in multi-organ dysfunction
requiring intensive care [11].
Pregnancy is considered a hypercoagulable state, with the aim
of protecting the laboring mother from excess blood loss. Physio-
logical changes in pregnancy include decrease in the level of pro-
tein S and increased levels of fibrinogen, von Willebrand factor
(vWF), factors II, VII, VIII, IX, and X by 20–1000%, reduction of
antifibrinolytic activity, and progressive platelet activation. The
levels of activated vWF-cleaving enzyme, a disintegrin and metal-
loproteinase with thrombospondin type 1 motif 13 (ADAMTS13)
have been shown to decrease as pregnancy progresses [12]. The
syncytiotrophoblast, like other endothelia, holds Weidel-Paladel
bodies, intracellular structures where vWF is released from in the
event of endothelial damage. In haemostasis, the vWF mediated
coagulation with fibrin deposition repairs the damaged villous tis-
sue and contains the damage.
Lesion or injury of the endothelium is a central feature of TMA
[13]. Thrombotic thrombocytopenic purpura (TTP) and atypical
hemolytic uremic syndrome (aHUS) are hallmark TMA disorders,
but other conditions are also associated with TMA. The underlying
etiology differs between these disorders, and it is thought that in
addition to underlying susceptibility, a second hit may be required
to trigger the events leading to TMA. TMA may be induced sec-
ondary to an infection, transplantation, medication, malignancy,
malignant hypertension, pregnancy/postpartum, or disseminated
intravascular coagulation (DIC).
In TTP, the plasma levels of ADAMTS13, are diminished due to,
for example, mutations in the ADAMTS13 gene. However, in major-
ity of cases, TTP is acquired and caused by induction of autoanti-
bodies against ADAMTS13. Decreased levels of ADAMTS13 lead to
unusually large activated vWF multimers on endothelial cells,
and cause platelet aggregation and microvascular thrombosis. Typ-
ical HUS is caused by shiga toxin-producing Escherichia coli (STEC-
HUS). AHUS is a complement-mediated disease, caused by defi-
ciencies in the alternative pathway of complement activation. In
aHUS, overt complement activation and endothelial cell activation
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of aHUS cases, there is a genetic defect in the complement system.2. Discussion
2.1. Genetics of preeclampsia
Preeclampsia carries a familial predisposition; the largest influ-
ence is derived from the maternal genotype [15,16]. Preeclampsia
is a complex disease with many loci contributing to the risk of dis-
ease, including variants associated with obesity and hypertension
[17]. Genetic associations fromangiogenic and immunological path-
wayshavebeendescribed in associationwithpreeclampsia [18–27].
Interestingly, genetics regulating the signaling of the natural
killer (NK) cells have provided evidence supporting the role of
the NK population in implantation and early placental develop-
ment [28]. Recently genetic exploration into the KIR-receptors on
NK cells and their ligands, HLA-C expressed on trophoblast cells,
have revealed an important direction for future studies in
preeclampsia [29–31].
In 2017, FLT1 coding for sFlt1 was established as the first candi-
date gene in preeclampsia studies. While low-frequency protective
coding variants were found in Finnish mothers, predisposing likely
regulatory alleles were identified in infants born from preeclamp-
tic pregnancies [18,19].2.2. Complement dysregulation predisposes to preeclampsia
Early studies in animal models have shown that complement
system is fundamentally important for the successful pregnancy.
Inhibition of C3 is crucial, as shown in Xu et al., who demonstrated
that without C3 inhibitor Crry all concepti were lost [32]. Certain
amount of C3 activation is needed for the normal placental devel-
opment [33]. In addition to its conventional role in complement
activation, C1q has been shown to be important in trophoblast
invasion [34]. Systemic complement activation is present during
normal pregnancy and further activation is observed in preeclamp-
sia, preeclampsia with IUGR, and HELLP [35]. However, a delicate
balance of activation and inhibition is a necessity [36–38]. The role
of the complement system is pronounced in early onset
preeclampsia. Furthermore, placental dysfunction is associated
with the early-onset and severe preeclampsia, often leading to
IUGR.
Among the immunological pathways, the complement system
has been the target of important investigative efforts in recent
years in preeclampsia and HELLP syndrome [35,39–42]. Inapt acti-
vation or insufficient regulation of the complement system may
have implications in early pregnancy by rejection of the invading
trophoblast cells, if complement activation results in an immune
response targeted against the trophoblasts. Complement may also
cause inflammation and systemic symptoms in late pregnancy, if
complement mediated phagocytosis of opsonized components is
inadequate [43]. While there is some indication of classical path-
way’s involvement in preeclampsia, most of the recent studies in
the field have highlighted the role of the alternative pathway of
complement activation [23,42,44–46].
Ma et al. showed elevated C5a deposition in the preeclamptic
placenta. The potent anaphylatoxin C5awas observed in the placen-
tal macrophages and C5a receptor (C5aR) expression colocalized
mainly with syncytiotrophoblast and trophoblasts in preeclamptic
placentas [41]. The expression of IL-1b, TNF-a, IL-6,MCP-1 and sFlt1
measured by mRNA, was significantly higher in preeclamptic pla-
centa, compared to normal pregnancy. The expression of these fac-
tors was shown to be upregulated in trophoblast cells after C5a
stimulation. Simultaneously PlGF and IL-10 were shown to be373decreased in preeclamptic placentas. Furthermore, after C5a stimu-
lation, their expression was reduced. The serum level of C5a was
shown to be significantly increased in preeclampsia patients when
compared to normal pregnancy. These findings shed light on not
only the role of the complement system in preeclampsia, but also
themechanisms underlying observed increased levels of sFlt1 levels
seen in preeclampsia.
In preeclampsia, the maternal symptoms are systemic and not
limited to placental deficiency.
The amount of placental debris is increased in the preeclamptic
pregnancy. To maintain healthy circulation, the placental debris
must be cleared by phagocytosis by maternal macrophages. Excess
burden of placental debris may cause the complement-mediated
clearance of placental particles to be overwhelmed, which may
result in exacerbated inflammation and activation of the immune
response [47].
Macrophages are known to limit the depth of trophoblast inva-
sion [48]. Phagocytosis by macrophages is dependent on several
receptors that signal downstream to induce a polarizing response
to favor either pro-inflammatory M1 or tolerogenic M2 population.
Complement receptors CR3 and CR4 on macrophages bind to the
opsonin iC3b. We have recently shown that altered iC3b binding
of complement receptors CR3 and CR4 on macrophages is associ-
ated with preeclampsia, suggesting possibly impaired clearing
function in preeclampsia [24]. Whether the CR3 and CR4 receptors
have a direct impact on trophoblast invasion remains to be
explored. 20% of early-onset cases are associated with hypoxia
and inadequate trophoblast invasion [49]. In preeclampsia, the
re-modulation of spiral arteries is inadequate, or occasionally in
severe cases, absent [50,51]. The constricted spiral arteries result
in a turbulent high-pressure blood flow that increases mechanical
shear stress to the placental villi. The turbulent blood flow into the
intervillous space may promote activation of the coagulation cas-
cade within the intervillous space [52].
2.3. vWF in preeclampsia
Disturbance in coagulation pathway is a central symptom of
TMA. Similarly, coagulation dysregulation is a feature of
preeclampsia [53,54]. Shared evolutionary history between coagu-
lation and complement cascades is reflected in the many interac-
tions between these two pathways.
In the preeclamptic placenta, vWF expression in the syncy-
tiotrophoblast is diminished, while intervillous vWF and maternal
plasma levels are increased [55]. The excess multimeric vWF
release due to syncytiotrophoblast damage bears potential for for-
mation of intervillous clots and could contribute to the increased
vWF that has been observed in the maternal circulation. In
preeclampsia, the plasma levels of free-floating ADAMTS13 is fur-
ther decreased likely due to depletion by excess vWF [56].
VWF has complex interactions with the complement system.
Recombinant factor H and partially purified factor H cleave soluble
vWF multimers, and full-length factor H have been shown to
enhance ADAMTS13 function [57,58]. Conversely, factor H inter-
acts with the vWF pathway of coagulation by inhibiting enzymatic
activity of ADAMTS13 [59]. It has been shown, that vWF protects
the endothelium from complement-mediated injury [60]. On the
other hand, evidence exists that activation of the vWF pathway
of coagulation may activate the alternative pathway of comple-
ment system [61].
While co-localization of vWF and factor H in endothelial cells
has been shown, this remains to be verified in the syncytium of
healthy and preeclamptic placenta [59]. However, we have seen
factor H intracellularly within the placental syncytiotrophoblast
and intracellular vWF in the syncytiotrophoblast has been reported
elsewhere (Fig. 1) [21,55].
Fig. 1. Factor H envelopes the placental villi circumferentially to protect the placenta from complement-mediated damage. An immunofluorescence staining from paraffin
section of week 34 placenta from a preeclamptic pregnancy after delivery by cesarean section. Blue staining shows nuclei (DAPI) and green factor H (dilution 1:1000, fitc). STB
indicates syncytiotrophoblast, the fetal-maternal interface with factor H staining. K indicates apoptotic syncytial knot. Arrowheads point to intracellular staining of factor H
on the syncytiotrophoblast. A – placental artery, V – placental vein, 200x magnification.
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capacity to aggravate the development of the TMA independently
of complement activation. Based on the contradictory results pre-
sented above, it seems that a certain balance is required between
the complement and vWF pathways to ensure adequate protection
and damage control, when protection against pathogens and tissue
injury repair is required, in order to prevent over-activation of
either complement or coagulation pathways. Therefore, slight
changes in the delicate balance might trigger a dangerous cascade
of events leading to, for example, TMA.2.4. Complement and angiogenetic factors in complicated pregnancy
Complement mediated endothelial disturbance and inflamma-
tion underliemany of the key symptoms of preeclampsia depending
on the targeted organ. If complement system fails to opsonize the
placental particles in the maternal circulation, they will promote
inflammation and clotting in the small vessels, likely contributing
to hypertension.When vascular endothelium is compromised, leak-
age exacerbated by complement-mediated vasodilationmay lead to
edema.When the basalmembrane of the kidney glomeruli lose pro-
tection by factor H, proteinuria follows [62]. Similarly to preeclamp-
sia, the symptoms seen in HELLP syndrome are related to
complement mediated endothelial damage [63].
Angiogenic imbalance is well-documented in preeclampsia [64].
A consensus now exists of the role of excess sFlt1 in preeclampsia
and it is among the best biomarkers for the disease. The role of sFlt1
in preeclampsia has been shown in biomarker studies [65,66], ani-
mal models [67,68], and most recently genetic association studies
[18,19]. During the second trimester of a pregnancy that will later
develop preeclampsia, an excess placental production of sFlt1 is
detectable from the maternal serum. Levels of sFlt1 typically corre-
late with the severity of preeclampsia [69]. Persisting high levels of
sFlt1 after preeclampsia have been associated with cardiovascular
morbidity during pregnancy and in later life [70]. Women with374preeclampsia are at an increased risk to develop cardiovascular dis-
ease and chronic kidneydisease in later life, especiallywithin5years
after the preeclamptic pregnancy [71-73].
Murine studies have added to the mechanistic understanding of
the complex relationships between the antiangiogenic sFlt1, the
complement system, and the vWF/ADAMTS13 arm of coagulation
cascade. An antibody-independent mouse model exploring sponta-
neous miscarriage and intrauterine growth restriction (IUGR)
showed that increased complement activation results in increased
levels of circulating sFlt1 [67]. Elegantly, Erpenbeck et al (2016)
showed using ADAMTS13-/- mouse model, that introducing over-
expression of sFlt1 results in TMA (thrombocytopenia, schistosyto-
sis, anemia, and VWF-positive microthrombi in multiple organs),
and recombinant human ADAMTS13 (rhADAMTS13) abolished
the classical features of TMA in these mice [68]. Furthermore,
monocytes can be stimulated to express an excess of sFlt1
in vitro, when exposed to C3a, an anaphylatoxin released by early
complement pathway activation and C5a, which is analogously
cleaved by activation of the terminal pathway of the complement
system. Release of the early complement anaphylatoxin C3a corre-
lates with upregulation of Flt1 expression by the syncytiotro-
phoblast in a terminal pathway-dependent way [50,51].
The mechanistic link between complement activation and sFlt1
further implicates the role of over-activation of complement in
preeclampsia pathogenesis. Interestingly, TMA can be induced by
certain drugs, including VEGF inhibitors, used in chemotherapy
[14,74]. Interesting aspect for future studies would be to analyze
the role of sFlt1 in severe preeclampsia from the perspective of
drug-induced TMA.3. TMA-like preeclampsia
Pregnancy combines different predisposing factors for TMA; the
physiological increase in coagulation factors and an increase of
vWF combined with decreasing levels of ADAMTS13. Furthermore,
Fig. 2. Pregnancy induced TMA. Hypothesis of pregnancy induced TMA. Pregnancy itself is an inflammatory and procoagulative state. In preeclampsia, inflammation is
exacerbated through placental dysfunction and released of shedding particles causing endothelial disturbance. Resulting changes are the over-activation of complement
system, and an anti-angiogenic and prothrombotic shift. Slight disturbances in the underlying control mechanisms might trigger TMA especially in women with pre-existing
genetic predisposition. Lightning arrows represents available and future targets for treatment.
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observed in increased levels of leukocytes and complement
activation.
Severe preeclampsia is akin to TMA diseases. Dysregulation of
complement system is indicated in both and coagulation distur-
bance is not uncommon in severe preeclampsia as evidenced by
HELLP, making diagnostic differences vague. In preeclampsia, the
defective placental development results in turbulent blood flow
into the placental bed and villous trees causing increased mechan-
ical stress to the villi and increased shedding of placental debris
into the maternal circulation. This increased placental debris in
the systemic circulation may cause endothelial injury, and in the
presence of pregnancy related changes in coagulation and comple-
ment system, may trigger TMA, including TTP or aHUS. In other
words, many preeclampsia patients might suffer from an under-
diagnosed TMA.
Pregnancy associated aHUS represented 16% of HUS cases
occurring in women aged between 18 and 45 years reported in
three national registries. Intriguing hints arise from the suscepti-
bility for TTP onset by pregnancy. TTP is a rare disease, with preg-
nancy induced TTP accounting for 10–30% of all adult cases of TTP
[75]. Considering the pregnancy-related decrease of ADAMTS13
levels, could preeclampsia, in discordant cases, present as a TTP-
like disease? In TTP treatment, a specific drug, caplacizumab-
yhdp, a nano-antibody, which inhibits the interaction between
vWF and platelets has been approved by the U.S. Food and Drug
Administration (FDA) in 2019.
HELLP syndrome is a TMA disorder that affects 0.5–0.9% of preg-
nancies. In HELLP syndrome, up to 46% of cases have been found to
have complement mutations [76]. In a recent review, Burwick and
Feinberg comprehensively summed up the literature concerning
complement in preeclampsia and HELLP syndrome. They observed
that complement mutations have been reported in altogether in
14% of severe preeclampsia and/or HELLP syndrome patients
[63]. Recently, Youssef et al. described blood proteomics of early-
onset severe preeclampsia [77]. The most different expression pat-
terns between preeclamptic patients and controls were discovered
in complement and coagulation pathways. Platelet function and
vWF were also indicated. These and other accumulating data sup-
porting complement disturbance in preeclampsia further corrobo-
rates that certain preeclampsia patients suffer from a TMA-like
disease even in the absence of some of the conventional criteria.
Based on the overactivation of complement system, they might375regardless benefit from anti-complement therapy, which is suc-
cessful in the treatment of TMA.
We therefore suggest a subtype of preeclampsia; TMA-
preeclampsia, and we propose laboratory investigations to detect
TMA in potential cases. The diagnostic criteria could be modified
from TMA diagnostics as follows: for TMA-preeclampsia, we pro-
pose the diagnostic criteria of thrombocytopenia
(thrombocytes < 100 E9/L) to indicated disruption of the coagula-
tion pathway, hemoglobin level < 100 g/L with erythrocyte frag-
mentation to indicate microangiopathic hemolytic anemia, and
alanine aminotransferase (ALT) > 100 U/L or serum creatinine
level > 100 lmol/L to indicate organ dysfunction in the pregnant
mother.4. Conclusions and perspectives
With many contributing phenomena, preeclampsia remains the
disease of theories. However, the accepted view is that preeclamp-
sia causes disturbance in the endothelium resulting in hyperten-
sion and proteinuria. Complement and coagulation are key
elements in the protection of the integrity of endothelium. Basic
research has proven the involvement of complement over-
activation in preeclampsia. HELLP syndrome is recognized as part
of the TMA disorders due to the well-documented complement
disturbance occurring in HELLP syndrome [63]. The full implica-
tions of the complex interactions between alternative pathway of
complement activation and vWF/ADAMTS13 activity for the TMA
pregnancy and preeclampsia remain to be explored.
We propose that a subtype of preeclampsia patients present
with a complement dysregulation-mediated TMA-like disease
(complement mediated TMA in preeclampsia). It is time to step
forward in the preeclampsia field. We now begin to unravel a
mechanistic view of the pathophysiology in a subphenotype of
preeclampsia (Fig. 2). As a significant subgroup of preeclampsia
patients show altered laboratory measurements indicative of
TMA type of disease, we urgently need to bring diagnostic tools
into the clinic, so that these different subtypes could be differenti-
ated. Combining pregnancy specific expertise and TMA diagnostics,
we could pinpoint a subgroup of patients who could benefit from
the advances of medicine, including next generation drugs with
specific target, such as eculizumab, which has been shown to abol-
ish aberrations in laboratory values indicating TMA in a case report
describing the treatment of a HELLP patient [78]. Other novel drugs
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Preeclampsia causes, in severe cases, very early prematurity and
need for intensive care treatment for the infant. Using eculizumab
could reduce the morbidity caused by prematurity and financial
cost from intensive care level treatment, not to mention the emo-
tional strain caused for the families.
To further support the proposition that a subtype of preeclamp-
sia could share the pathogenetic mechanisms behind other TMA,
interesting findings have been made through the COVID-19 out-
break. Some pregnant women with severe COVID-19 infection
replicate preeclampsia symptoms, and a recent study proposed
tools for differentiation of true preeclampsia from COVID-19
induced form [80]. In conclusion, COVID-19 has proven what we
postulated based on the accumulating data on complement and
preeclampsia i.e. preeclampsia, similarly to HELLP syndrome is,
in discordant cases, a TMA disorder.
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